Literature DB >> 8109683

Venous ulcers.

C S Burton1.   

Abstract

Successful therapy of venous ulcers combines local wound treatment modalities and ambulatory hemodynamic support to control the underlying disease. Compression bandaging reduces or eliminates edema, and a moist wound environment not only debrides necrotic tissue but also aids development of granulation tissue, a prerequisite for epidermal repair. We have occluded chronic wounds, known to be heavily colonized, with a hydrocolloid dressing for up to 7 days and found that soft-tissue infections occurred in only 1% of all dressing changes in our clinic, compared with 6.5% generally reported in the literature. In venous ulcers, resident bacteria may be beneficial in that their proteolytic activity assists with autolysis of fibrinopurulent wound exudate. The importance of lysing fibrin and reducing the number of existing fibrin "cuffs," thereby improving local tissue oxygenation and nutrient/waste exchange, is not completely understood; however, this phenomenon, in part, may explain the excellent clinical results obtained with one type of hydrocolloid dressing (DuoDERM), which has been shown to lyse fibrin more effectively than other types of moisture-retentive and hydrocolloid dressings.

Entities:  

Mesh:

Year:  1994        PMID: 8109683     DOI: 10.1016/0002-9610(94)90009-4

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  2 in total

1.  Evaluation of dermal pericapillary fibrin cuffs in venous ulceration using confocal microscopy.

Authors:  Kendra L Kobrin; Paul J Thompson; Martijn van de Scheur; Tae-Hee Kwak; Saerom Kim; Vincent Falanga
Journal:  Wound Repair Regen       Date:  2008 Jul-Aug       Impact factor: 3.617

2.  Survey of bacterial diversity in chronic wounds using pyrosequencing, DGGE, and full ribosome shotgun sequencing.

Authors:  Scot E Dowd; Yan Sun; Patrick R Secor; Daniel D Rhoads; Benjamin M Wolcott; Garth A James; Randall D Wolcott
Journal:  BMC Microbiol       Date:  2008-03-06       Impact factor: 3.605

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.